Work

Analysis of tumour hyperprogression (HP) with nivolumab (Nivo) in randomized, placebo (Pbo)-controlled trials

Year: 2019

Type: article

Source: Annals of Oncology

DOI: 10.1093/annonc/mdz253.019

Authors: M. Reck, Y. Feng, H.R. Kim, G. Plautz, Y.-K. Kang, T.K. Owonikoko, P. Nghiem, J. Sheng

Institutions: German Center for Lung Research, LungenClinic Grosshansdorf, Bristol-Myers Squibb (United States), Yonsei University, Yonsei Cancer Hospital, University of Ulsan, Emory University, Winship Cancer Institute, University of Washington, Fred Hutch Cancer Center

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2978744111

FWCI:

Cites:

Cited by:

Related to: 10